Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alam Khan

Internal Medicine Chicago, IL Medical Doctor

NPI 1316946288 CMS profile 14542

2800 N. Sheridan Rd, Suite 400, Chicago, IL 60657

Open in the dashboard

General payments

$9,715

467 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alam Khan of Chicago, IL is reported in the CMS Open Payments database as having received $9,715 across 467 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $685 27
2024 General $1,277 56
2023 General $1,515 71
2022 General $1,093 56
2021 General $1,713 86
2020 General $1,594 81
2019 General $1,838 90

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alam Khan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Alam Khan were reported at $685. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Alam Khan Internal Medicine median Middle half National median
2019 $1,838 $159 $48–$570 $163
2020 $1,594 $119 $33–$402 $114
2021 $1,713 $135 $37–$521 $132
2022 $1,093 $141 $42–$496 $149
2023 $1,515 $149 $45–$519 $160
2024 $1,277 $154 $47–$537 $164
2025 $685 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $1,299 59 payments
  2. Novo Nordisk Inc $783 46 payments
  3. Novartis Pharmaceuticals Corporation $780 37 payments
  4. Teva Pharmaceuticals USA, Inc. $769 31 payments
  5. AbbVie, Inc. $727 42 payments
  6. Amgen Inc. $653 27 payments
  7. Janssen Pharmaceuticals, Inc $612 23 payments
  8. Napo Pharmaceuticals Inc $533 26 payments
  9. Gilead Sciences, Inc. $461 20 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $365 16 payments
  11. Other $2,734 140 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,310 453 payments
  2. Education $230 5 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $175 9 payments
Products named General payments · program years 2019–2025
  1. ELIQUIS Cardiovascular;Metabolic Disease $943 41 payments
  2. XARELTO $568 21 payments
  3. Mytesi $533 26 payments
  4. Ozempic $495 30 payments
  5. VRAYLAR $479 30 payments
  6. LEQVIO $389 15 payments
  7. EVENITY $369 13 payments
  8. AUSTEDO $356 20 payments
  9. ENTRESTO $344 19 payments
  10. ELIQUIS Cardiovascular $326 17 payments
  11. Other $6,683 333 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 189 drugs

Part D claims

10,926

Median for Internal Medicine: 777

Drug cost

$909,618

Median for Internal Medicine: $73,373

Branded share of claims

24.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 452 $204,353
Jardiance Empagliflozin Brand 86 $42,789
Xifaxan Rifaximin Brand 44 $39,144
Ozempic Semaglutide Brand 26 $38,174
Invega Sustenna Paliperidone Palmitate Brand 13 $32,349
Lokelma Sodium Zirconium Cyclosilicate Brand 44 $28,672
Xarelto Rivaroxaban Brand 66 $28,204
Myrbetriq Mirabegron Brand 50 $27,811
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 26 $24,085
Incruse Ellipta Umeclidinium Bromide Brand 61 $23,598

The 10 drugs with the highest cost, of 189 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$119,241

Of which drugs: $1,227

Medicare patients

377

Average age 79

Services billed

1,783

210 women, 167 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Heart failure 39%
Diabetes 38%
Ischemic heart disease 37%
Depression 36%
Chronic kidney disease 33%
Atrial fibrillation 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 14 14 $1,145

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $194
  • Otsuka America Pharmaceutical, Inc. $62
$257 — —
Mytesi
  • Napo Pharmaceuticals Inc $151
$151 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $137
$137 37 —
VRAYLAR
  • AbbVie, Inc. $118
$118 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $89
$89 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

467 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record